By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
The panel consensus is bearish on Canopy Growth, citing concerns about stagnant recreational growth, international sales decline, and persistent unprofitability despite medical cannabis growth. The key risk is the company's inability to translate revenue gains into sustained profitability, while the key opportunity is the potential regulatory arbitrage in the US market.
Risk: Inability to translate revenue gains into sustained profitability
Opportunity: Potential regulatory arbitrage in the US market
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Companies try to highlight the best news when they report earnings. That's to be expected, but you need to go into earnings season knowing you have read beyond the headlines. Canopy Growth (NASDAQ: CGC) reported huge growth in its medical marijuana business, which saw revenues increase 27% in the fourth quarter of fiscal 2026 and 17% for the full fiscal year. The rest of the business was a bit more mixed.
There's no question that Canopy Growth's medical marijuana business is doing well right now. It is also worth noting that the company recently bought MTL Cannabis, a move that should solidify its already strong position in the Canadian medical marijuana market. The strong growth in medical marijuana revenues highlights why the company is leaning into this division.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
The problem is that this isn't the company's only business. Its recreational marijuana business increased revenue by 20% in fiscal 2026, but the fourth quarter saw only a 1% increase. While the company attributes the full-year growth to "growth in infused PRJ offerings and new All-In-One vaporizers launched early in the fiscal year," the fourth quarter's 1% revenue growth suggests it ended the year on a weak note. That hints this division's outlook may not be as robust as the full-year growth suggests.
Meanwhile, the company's international cannabis sales rose 68% in the quarter, but fell 7% year over year. Supply chain issues were highlighted as a problem earlier in the year. Once again, the outlook is less clear than investors may like. And then there's the Storz & Bickel vaporizer business, which saw sales decline 14% for both the full fiscal year and in the fourth quarter.
It is likely to require more than one strong division for Wall Street to get excited about Canopy Growth again. But there's still some more bad news to consider. Notably, the company's gross margin fell four percentage points in the fourth quarter and six percentage points for the full fiscal year.
Not surprisingly, Canopy Growth reported negative earnings again in fiscal 2026. In fact, it hasn't reported positive earnings since it went public, more than a decade ago. Now add in the fact that it recapitalized its balance sheet in fiscal 2026, exchanging shares for debt, and most investors should probably watch from the sidelines.
Could Canopy Growth's stock rally from here? Sure. But with only one business clearly performing well, only the most aggressive investors should probably bet on this penny stock having a sustained rally.
Before you buy stock in Canopy Growth, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Canopy Growth wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $398,052! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,181,688!
Now, it’s worth noting Stock Advisor’s total average return is 892% — a market-crushing outperformance compared to 205% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of June 28, 2026. *
Reuben Gregg Brewer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"Persistent losses and margin erosion, plus a debt-heavy balance sheet, make a sustained rally unlikely without a credible profitability plan the article does not establish."
Canopy Growth's medical cannabis growth is the bright spot, but the rest of the business looks fragile. Q4 medical revenue +27% y/y; full-year +17%. Recreational growth +20% but only +1% in Q4; international sales +68% in the quarter yet -7% YoY; Storz & Bickel down 14%. Gross margin fell 4 ppts in Q4 and 6 ppts for the year, and the company remains unprofitable, with a balance sheet recapitalized via debt-for-equity. The article glosses over what truly matters: whether these revenue gains can translate into sustained profitability amid dilution risk, supply-chain issues, and regulatory pressures. Until margins stabilize, the rally looks precarious.
Counterpoint: if Canopy can stabilize costs, resolve international bottlenecks, and monetize medical revenue through higher-margin products, a re-rating is plausible even without immediate GAAP profitability.
"Canopy's deteriorating gross margins and stagnant recreational revenue indicate that their core business model remains fundamentally broken despite pockets of growth."
Canopy Growth (CGC) remains a classic value trap. While the 27% growth in medical cannabis is a bright spot, the 600-basis-point contraction in annual gross margins is the real story. It signals that even as they scale, they are losing pricing power or facing unsustainable production costs. The pivot to debt-for-equity swaps in fiscal 2026 is a desperate move to stave off insolvency rather than a strategic capital optimization. With recreational growth stalling at 1% in Q4 and the Storz & Bickel hardware business cratering, there is no clear path to positive EBITDA, let alone GAAP profitability. Investors are essentially betting on a regulatory miracle rather than a functioning business model.
If Canopy successfully executes a 'lean' operating model post-recapitalization, their established infrastructure could make them the primary acquisition target for a major CPG or tobacco firm looking to enter the North American market at a depressed valuation.
"CGC's medical strength masks accelerating weakness in three other divisions and a decade of unprofitability that suggests structural, not cyclical, problems."
The article cherry-picks one bright spot (medical +27% Q4) while burying structural rot: recreational decelerated to 1% Q4 growth, international fell 7% YoY despite headline 68% quarterly bounce, Storz & Bickel collapsed 14%, and gross margins compressed 6 points full-year. Most damning: CGC has never posted positive earnings in 10+ years as a public company and just recapitalized debt into equity—a distress signal. One division growing doesn't fix a company burning cash across three others. The MTL Cannabis acquisition is a defensive move, not a growth catalyst.
Medical marijuana legalization tailwinds in Canada remain real, and if CGC can stabilize recreational (1% Q4 is a floor, not a trend) while scaling medical, the 27% medical growth could compound into meaningful EBITDA within 18 months—making today's beaten-down valuation a value trap that catches shorts.
"Medical growth alone cannot offset CGC's segment volatility, margin erosion, and decade-long losses without measurable improvement in the other three businesses."
Canopy Growth (CGC) shows clear medical-segment momentum with 27% Q4 and 17% full-year revenue gains plus the MTL Cannabis deal, yet the article underplays how recreational's Q4 stall at 1%, international swings, and Storz & Bickel's 14% drop expose execution risk across non-medical lines. Gross-margin compression of four to six points and another year of losses keep the cash-burn profile unattractive. Without evidence that medical scale can lift consolidated margins or that recreational volume rebounds, any rebound remains speculative rather than fundamental.
A rapid Canadian medical-market consolidation after the MTL deal could lift overall gross margins faster than modeled, turning the current loss trajectory and allowing a re-rating even if recreational stays flat.
"Debt-for-equity refit may reduce liquidity risk, but the real test is whether Canopy can translate medical growth and the MTL deal into true EBITDA; without that, the upside is speculative."
Gemini's 'value trap' thesis hinges on margin compression and debt-for-equity swaps as a negative signal. My flip side: that balance-sheet refit could unlock optionality from the MTL Cannabis deal via scale and cross-sell to medical customers. The risk Gemini ignores is execution risk in turning medical growth into consolidated profitability; if that fails, the stock remains speculative, even as a potential re-rating path exists on higher-margin medical monetization.
"The debt-for-equity swap is a strategic preparation for US federal rescheduling, not just a sign of financial distress."
Claude, you’re missing the regulatory arbitrage here. Everyone is hyper-focused on Canadian recreational stagnation, but the real play isn't Canadian market share—it's the US-listed 'Canopy USA' structure. By isolating the US exposure, CGC is essentially a call option on federal rescheduling. If the DEA moves cannabis to Schedule III, the balance sheet restructuring isn't a 'distress signal'; it’s a clearing of the deck to facilitate a U.S. capital injection or acquisition that currently remains legally blocked.
"Regulatory optionality on US rescheduling doesn't solve the near-term cash-burn problem or justify holding a perpetually unprofitable core business."
Gemini's US rescheduling arbitrage is clever, but it's speculation layered on speculation. The Canopy USA structure exists, yes—but federal legalization doesn't automatically unlock value if CGC's core Canadian business remains unprofitable. We'd be betting on regulatory tail risk to justify holding a company hemorrhaging cash today. More immediate: if recreational stays at 1% Q4 growth, medical's 27% alone won't offset consolidated burn. The balance-sheet swap buys time, not salvation.
"US rescheduling won't offset Canadian operational losses without margin stabilization first."
Gemini's Canopy USA rescheduling bet overlooks how the 4-6 point gross margin compression and persistent Canadian cash burn will continue draining resources even after any DEA Schedule III shift. The MTL acquisition strengthens medical scale domestically but provides no capital bridge or margin lift to US assets, meaning injected funds risk immediate dilution rather than enabling a clean acquisition play.
The panel consensus is bearish on Canopy Growth, citing concerns about stagnant recreational growth, international sales decline, and persistent unprofitability despite medical cannabis growth. The key risk is the company's inability to translate revenue gains into sustained profitability, while the key opportunity is the potential regulatory arbitrage in the US market.
Potential regulatory arbitrage in the US market
Inability to translate revenue gains into sustained profitability